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Abstract 
Altered cardiac energetics and calcium handling are characteristic features of 
cardiovascular disease. Mitochondria play a significant role in both cellular energy 
generation and calcium homeostasis and may be a key integration point of these two 
systems. Calcium uptake into mitochondria occurs via a recently identified mitochondrial 
calcium uniporter complex.  
In the first part of this thesis, I characterize the phylogenomic distribution of the 
uniporter’s membrane spanning pore (MCU) and regulatory subunits (MICU1 and 
MICU2). Homologs of both MCU and MICU1 tend to co-occur in all major branches of 
eukaryotic life but both have been lost along certain protozoan and fungal lineages. 
MICU2 represents a recent duplication of MICU1. Several bacterial genomes also 
contain putative MCU homologs that may represent prokaryotic calcium channels.  The 
analyses indicate that the uniporter may have been an early feature of mitochondria. 
In the second part of this thesis, I perform transcriptome wide analysis of human 
and mouse cardiomyopathy datasets and identify MICU2, a regulatory component of the 
mitochondrial calcium uniporter, as one of six genes consistently upregulated in cardiac 
disease states. I test the hypothesis that increased MICU2 expression is cardio-
protective by generating a global Micu2-/- mouse.  These mice have diastolic 
dysfunction. Isolated Micu2-/- cardiomyocytes show altered sarcomere relaxation and 
cytosolic calcium reuptake kinetics and Micu2-/- ventricular tissue has transcriptional 
dysregulation of genes encoding sarcomere proteins and bZIP transcription factors. 
When exposed to two weeks of angiotensin 2, a pharmacologic hypertrophic stimuli, 
Micu2-/- mice exhibit both systolic and diastolic dysfunction.  
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Additionally, ~30% of Micu2-/- mice exposed to angiotensin 2 died within the first 
week from abdominal aortic rupture. The increase in abdominal aortic diameter is 
angiotensin 2 dose dependent. Norepinephrine treatment does not cause abdominal 
aorta dilatation, suggesting an angiotensin 2 specific effect rather than a blood pressure 
mediated effect. Transcriptional profiling of angiotensin treated Micu2-/- aortas show 
evidence of extracellular matrix remodeling due to matrix metaloprotease activity. 
Single-cell RNA-seq of aorta treated with angiotensin 2 identified differential expression 
of reactive oxygen species, inflammation and proliferation genes in fibroblast and 
smooth muscle cells, suggesting an early mechanism triggering aneurism formation. 
Together, these data point to a significant and previously unappreciated role for Micu2 
in maintaining both cardiac and vascular homeostasis.  
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Glossary 
CVD: Cardiovascular disease 
HCM: Hypertrophic cardiomyopathy 
DCM: Dilated cardiomyopathy 
MCU: Mitochondrial Calcium Uniporter  
MICU1: Mitochondrial calcium uptake protein 1 
MICU2: Mitochondrial calcium uptake protein 2  
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Introduction   
Cardiovascular disease, heart failure and cardiomyopathy 
Cardiovascular disease (CVD) is the leading cause of death in the United States 
and is responsible for 17% of national health expenditures (1). Although cardiovascular 
disease comes in many forms, a significant proportion of this disease burden is due to 
heart failure, a complex clinical syndrome that results from any structural or functional 
impairment of ventricular filling or ejection of blood (2). The lifetime risk of developing 
heart failure is 20% for Americans over the age of 40 and increases with age, thus the 
burden of disease is expected to grow significantly in the coming decades (3, 4). The 
total cost of heart failure associated healthcare in the United States exceeds $30 billion 
annually, or approximately 1% of all US healthcare spending (5). 
The majority of heart failure is associated with cardiomyopathies a 
heterogeneous group of diseases of the cardiac muscle associated with mechanical 
dysfunction that result in inappropriate ventricular hypertrophy (HCM) or dilatation 
(DCM) (6-8). While the two disease entities are quite distinct in terms of natural history, 
both HCM and DCM may be caused by mutations in the genes that encode the protein 
constituents of the cardiac sarcomere, the contractile apparatus of the cardiac myocytes 
(9). Despite our increasingly complete enumeration of mutations that cause 
cardiomyopathy, progress elucidating mechanisms amenable to therapeutic intervention 
has been more limited (10). 
Altered Cellular Energetics and Calcium Signaling Cause Cardiomyopathy 
Work over the past 50 years demonstrates that altered cardiac energetics is the 
mechanistic cause of cardiomyopathy (11-13). Sarcomere protein gene mutations, the 
most common genetic cause of HCM and DCM, alters cardiomyocyte 
excitation/contraction coupling, which directly or indirectly results in altered 
cardiomyocyte energetics (14-17). One leading hypothesis is that changes in sarcomere 
function leads to cellular calcium fluxes, which in turn alters the balance of energy 
utilization and production in an individual cardiomyocyte (18, 19). The myocyte adapts 
to this change in energy homeostasis by reactivating fetal gene programs as well as 
8 
 
inducing fibrosis and maladaptive cardiac remodeling which results in cardiac 
remodeling (20, 21). 
Directly altering cardiomyocyte energetics, as is often the case in patients with 
mitochondrial disease, also causes cardiomyopathy (22). Notably, cardiac muscle 
disease is a common feature of patients with maternally inherited mitochondrial 
disorders such as MELAS and MERRF (23), as well as in patients with Mendelian 
disorders of oxidative phosphorylation, including those due to mutations in TMEM70 
(24), AGK (25) and AARS2 (26).  Outside of the cardiovascular system, altered cellular 
energetics in patients with mitochondrial disease commonly cause a range of disease 
phenotypes including diabetes, neurological disease, vision loss, and deafness (22). 
Less commonly, patients with mitochondrial disease have been described with aortic 
dilation (27) and aortic rupture (28). 
Mitochondria Integrate Cellular Energetics and Calcium Homeostasis 
Mitochondria are a primary source of energy in eukaryotic cells, but also play a 
major role in diverse cellular metabolic and homeostatic processes. Mitochondria have 
an endosymbiotic origin and retain many features of their proto-bacterial ancestor, 
including a double membrane and a circular genome. They also resemble bacteria in 
that they are typically about one micron in length and constantly move, divide and fuse 
to form a dynamic network (29). The majority of what was once the proto-mitochondrial 
genome has been transferred to the eukaryotic nuclear genome over billions of years of 
co-evolution. Of the ~1,000 mitochondrial proteins, about two-thirds have bacterial 
origins from multiple bacterial phyla. (30). 
Mitochondria generate energy through the respiratory chain which enables 
oxidative phosphorylation. The respiratory chain consists of four complexes that 
catalyze electron transfer from reducing equivalents to molecular oxygen. Free energy 
is conserved by coupling electron transport to the formation of a proton gradient, or 
proton motive force, by three of these complexes (I, III and IV), which is then dissipated 
by F1F0-ATPase (complex V) for ATP synthesis (31). Many biochemical processes are 
coupled to the proton motive force including NADPH generation through nicotinamide 
nucleotide transhydrogenase (32), ATP/ADP exchange through the adenine nucleotide 
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translocator (33), protein import through the translocase of the inner mitochondrial 
membrane (34), inorganic phosphate transport (35) and calcium transport (36). 
Mitochondria from different organs exhibit distinct patterns of fuel use and 
biosynthetic capacities. For example, adrenal mitochondria are capable of high capacity 
steroid hormone biosynthesis, while skeletal-muscle mitochondria specialize in fatty 
acid oxidation (29). Even within individual cells, mitochondria exhibit marked 
heterogeneity: intermyofibrillar and subsarcolemmal mitochondria have distinct fuel 
preferences and differential responses to stress in both skeletal muscle and cardiac 
muscle (37, 38). 
Given the significant energy requirements of cardiac muscle it is unsurprising that 
tight coupling exists between cardiomyocyte and mitochondria (39, 40). Much of this 
coupling is thought to be mediated by calcium (41). 
The Mitochondrial Calcium Uniporter 
One remarkable feature of vertebrate mitochondria is their ability to uptake and 
buffer large amounts of calcium via a channel called the mitochondrial calcium 
uniporter. Its activity was first documented 50 years ago when two groups 
simultaneously discovered that mitochondria take up and buffer large amounts of 
calcium when treated with phosphate (42, 43). Later studies showed that this calcium 
transport across the mitochondrial inner membrane occurs through a uniporter, which 
transports calcium in an electrogenic manner, thereby dissipating the membrane 
potential generated by the respiratory chain, without requiring co‑transport with an 
anion or exchange for another cation (44). Flux studies in isolated mitochondria 
suggested the existence of a channel mechanism that was remarkably selective for 
calcium (45). Subsequent studies showed that the primary route for mitochondrial 
calcium efflux is electroneutral exchange with sodium (46) or hydrogen (47, 48). 
The molecular identity of the uniporter remained elusive until integrative genomic 
methods revealed its pore-forming protein MCU (49, 50), and regulatory subunits EMRE 
(51), MICU1 (52), MICU2 (53). Mitochondrial calcium uptake activity is abolished by 
mutations affecting key acidic residues in MCU act as a calcium selectivity filter (49). 
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The MCU homologue in dictyostelium discoideum is by itself sufficient to reconstitute 
mitochondrial calcium transport when expressed in yeast, which lacks uniporter 
components (54). However, human MCU alone is insufficient to transport calcium. 
EMRE, a metazoan specific protein that is part of the uniporter complex, is necessary 
for uniporter activity in mammalian cells. Heterologous co-expression of EMRE and 
human MCU is sufficient to reconstitute uniporter activity in yeast (51, 54). Furthermore, 
EMRE mediates the interaction of MCU with regulatory subunits MICU1 and MICU2 
(51).  
MICU1 and MICU2 function as a gatekeeper that sets the threshold of extra-
mitochondrial calcium concentration for uptake of calcium into mitochondria (55-57). 
MICU2, which is a paralogue of MICU1, is closely linked to MICU1 both physically and 
functionally (53). Knockout of either MICU1 or MICU2 in mammalian cells results in 
mitochondria taking up calcium at a lower threshold of calcium concentration (56). The 
two components are localized to the inter-membrane space (52, 53). The emerging 
model is that the combination of MICU1 and MICU2 regulates the uniporter to prevent 
calcium at low concentration from passing through (58).  
Genetic perturbation of uniporter components enables evaluation of how 
mitochondrial calcium uptake contributes to homeostasis and disease (59). On a cellular 
basis, perturbation of the uniporter is associated with apoptosis (60), the generation of 
mitochondrial reactive oxygen species (60), oncogene-induced senescence (61), matrix 
dehydrogenase activation and metabolic coupling (62), leukotriene receptor signaling 
(63), neuron excitotoxicity (64) and glucose stimulated insulin secretion (65). In whole 
animal models, loss of MCU can also be tolerated in mice with a mixed genetic 
background (62). These mice exhibit altered skeletal muscle metabolism and peak 
performance, however these mice did not have grossly altered cardiac function at 
baseline or in response to stress from an isoproterenol challenge or transverse aortic 
constriction.(62, 66) MCU knockout was found to be lethal for C57BL/6 mice, whereas 
knockout mice with an outbred CD1 background were viable (67). MCU knockout CD1 
mice were overtly normal but had reduced exercise tolerance (67). Loss of uniporter 
activity in mice sinoatrial node cells through the overexpression of a dominant-negative 
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MCU protein revealed that mutant mice had a blunted increase in heart rate in response 
to β‑adrenergic stimuli (68). Expressing this protein throughout the heart revealed 
altered cardiac oxygen utilization, cytoplasmic Ca2+ homeostasis, and pathologic 
responses to ischemia-reperfusion injury (69). MCU has also been shown to play a key 
role in matching cardiac metabolism to contractile stress (70, 71). 
In humans, truncating mutations in MICU1 that lead to complete loss of its 
expression result in a Mendelian syndrome of skeletal muscle myopathy, learning 
disability and movement disorder (72). The impact of mutations in other uniporter 
components in human patients have not yet been reported. 
Purpose of inquiry & Hypotheses  
This thesis investigates the evolutionary history of the mitochondrial calcium 
uniporter and evaluates how mitochondrial uniporter dysfunction causes cardiac and 
vascular pathology. 
The first part of this thesis systematically explores the taxonomic distribution and 
evolutionary history of the mitochondrial calcium uniporter. We hypothesize that 
systematic annotation of uniporter components across a range of diverse evolutionary 
taxa will enable inference about its evolutionary history. We test this hypothesis by 
utilizing the availability of a large and diverse array of recently sequenced eukaryotic 
genomes and systematically annotating these for the Uniporter. We then build a 
phylogenomic tree of eukaryotic life and analyze the gain and loss of uniporter 
components in the context of this phylogenomic tree. 
The second part of this thesis describes the contribution of uniporter component 
MICU2 to cardiac and vascular homeostasis and pathophysiology. Transcriptome 
analysis of cardiomyopathy tissue from human patients and mouse models identifies 
>1000 genes that are differentially expressed in cardiomyopathy tissues (73, 74). We 
hypothesize that key mediators of cardiomyopathy should be consistently dysregulated 
in human patients with cardiomyopathy and mouse models of human cardiomyopathy. 
Hence these key mediators can be identified with a bioinformatic screen. Only six genes 
are consistently dysregulated across all transcriptome datasets, one of which is 
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uniporter component MICU2. We hypothesize that loss of MICU2 function will increase 
susceptibility to cardiovascular disease. We test this hypothesis profiling the cardiac and 
vascular phenotypes of a Micu2-/- knockout mouse.  
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Methods 
Phylogenomic matrix of 162 eukaryotic species 
Eukaryote genome and proteome data were downloaded from the KEGG 
Organisms Database, Release 58 (75). Six recently generated and annotated genomes 
were obtained from the Broad Institute Origins of Multicellularity Sequencing project 
(76): T.trahens, C.owczarzaki, S.arctica, S.rosetta, A.macrogynus and S.punctatus. 
Homologous proteins for each M. musculus protein were identified using pairwise 
BLASTP (77) (Expect<0.001) in each of the 162 sequenced eukaryotes, retaining the 
top homolog. 
Phylogenomic tree reconstruction 
A phylogenomic tree was constructed based on the methodology of Ciccarelli et 
al. (78). The following 16 highly conserved proteins (present in E. coli  and in ≥98% of 
the 162 eukaryote genomes) were concatenated, interspersed with a 20-amino acid 
spacer sequences, and aligned using MUSCLE (79) (default parameters): Hars, Hspd1, 
Mlh1, Nthl1, Sars, Sod2, Top3a, Vars, Rps3, Uba2, Rpl23, Farsa, Ola1, Ddx47, Elp3, 
Qars. Five species were removed due to poor sequence alignment: M.oryzae, 
M.guilliermondii, S.stipitis, P.placenta and X.laevis. A species tree was constructed via 
Neighbor-Joining using MEGA 5.05 (80). Evolutionary distances were computed 
(Poisson correction) in units of amino acid substitutions per site assuming equal amino 
acid frequencies and substitution rates across sites, while correcting for multiple 
substitutions at a site. After removing ambiguous positions, there were 34844 pairwise 
aligned positions.  Tree visualization was performed by iTOL (81), using the optimal tree 
with the sum of branch length of 26.  The tree was manually compared to previous 
phylogenetic reconstructions (78, 82), and manually labeled with taxonomic branch 
names (e.g. Metazoa) for clarity.  The reconstructed tree was consistent with published 
reconstructions (8, 19-24) or NCBI taxonomy except in four regions: mammals (Bos 
taurus, Canis lupus familiaris, Mus musculus, Sus scrofa), primitive metazoans 
(Nematostella vectensis, Hydra magnipapillata, Strongylocentrotus purpuratus, 
Trichoplax adhaerens), one insect (Pediculus humanus corporis), and three highly 
divergent fungal/protist species (Encephalitozoon cuniculi, Entamoeba histolytica, 
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Entamoeba dispar) perhaps due to well-established complications of phylogenomic 
reconstruction such as long-branch attraction (82). 
Identification of MCU and MICU1 homologs 
Putative homologs of M. musculus MCU and MICU1 were identified by bi-
directional BLASTP homolog. These automated results required refinement, since for 
example the top BLASTP result for MCU in B. Malayi is Bm1_07575 which is not a bi-
directional hit and lacks the DIME motif and protein structure fundamental to the 
uniporter.  Therefore, putative MCU homologs were accepted as valid homolog if 
computational algorithms identified three features: (i) a conserved DIME motif when 
aligned with MUSCLE (79) or manual inspection, (ii) two transmembrane domains 
flanking the DIME motif as identified with TMHMM(83), (iii) two coiled-coil domains 
surrounding the transmembrane domains or circularly permuted as identified with 
COILS (84). One homolog lacking a coiled-coil domain was retained after inspection 
(Selaginella moellendorffii). Proteins were annotated for mitochondrial targeting 
sequences (MTS) with Mitoprot (85), but MTS presence was not required for homology.  
We further explored the number of MCU homologs in each organism by counting 
how many proteins had a BLASTP top hit of MCU or CCDC109B and met this 
refinement criteria. Interestingly, three species of metaphyta (Vitis vinifera, Populus 
trichocarpa and Brachypodium distachyon) had MCU homologs containing chloroplast 
targeting signals in place of an MTS. 
Bacterial homologs were identified by iterative PSI-BLASTP followed by manual 
inspection and by presence of DUF607 within the PFAM database.  These two methods 
independently identified three putative homologs: Chlorobium phaeobacteroides 
A1BIL6, Prevotella oris D1QQZ1, and Cytophagia hutchinsonii Q11Z39.  Each homolog 
contained conserved residues near the DIME motif (although the essential acidic 
residues were not conserved in C. phaeobacteroides), flanking transmembrane 
domains identified by TMHMM, and coiled-coil domains identified by COILS. 
A similar refinement strategy was required for MICU1 homology, since in several 
species the EF-hand containing proteins ARALAR1 and SLC25A13 were identified as 
top BLASTP hits but are not bi-directional hits or functional homologs. Putative MICU1 
homologs were considered valid if the alignment covered ≥80% of the query protein and 
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INTERPRO (86) identified ≥2 aligned EF-hand domains without additional protein 
domains (e.g. mitochondrial carrier protein domains).  
MICU2 mouse generation 
The Micu2 mice were derived from the TG0122 (Efha1) gene-trap insertion site in 
the OST409343 OmniBank®ES cell line, which was acquired from Lexicon. The mice 
were backcrossed on to the C57/B6 background for >10 generations. All animal 
experiments and procedures were approved by the Harvard Medical School IACUC. 
Mouse liver mitochondrial Isolation and calcium uptake analysis  
Mitochondria were isolated from mouse liver using differential centrifugation as 
previously described (53) and resuspended in 220 mM mannitol, 75 mM sucrose, 10 
mM HEPES pH 7.4, 1 mM EDTA, and 0.2% BSA and kept on ice.  Calcium uptake 
assays were performed by adding 120 ug mitochondria to 150 uL buffer containing 125 
mM KCl, 2 mM K2HPO4, 1 mM MgCl2, 20 mM HEPES at pH 7.2, 5 mM glutamate and 
malate, and 1 μM Oregon Green-Bapta6F. Fluorescence was monitored using a Perkin-
Elmer Envision plate reader in response to various pulses of CaCl2. Relative rate of 
calcium uptake is reported using a linear fit of fluorescence from 30-40 s (n≥3). 
Mouse echocardiography and abdominal ultrasonography 
Mice were anesthetized with an isoflurane vaporizer (VetEquip), and each limb 
was placed on the ECG leads on a Vevo Mouse Handling Table (VisualSonics Inc.), 
maintaining the body temperature at 37°C during the study. Transthoracic 
echocardiography and trans-abdominal ultrasonography was performed using Vevo 
2100 High-Resolution In Vivo Micro-Imaging System and MS550D transducer 
(VisualSonics Inc.), with heart rate at 500–550 bpm. The images were acquired as 2D 
(left parasternal long and short axes), M-mode (left parasternal short axis), speckle 
tracking and trans-abdominal 2D measurements. Measurements were averaged from 
images acquired during 3 consecutive heart beats. All echocardiographic and 
ultrasonographic measurements were performed with an experienced operator blinded 
to mouse genotype. Differences between groups of mice were determined using the 
unpaired Student's t-test. 
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Single Myocyte Functional Profiling 
Ventricular cardiomyocytes from three pairs of adult WT and Micu2-/- littermates 
at 6-8 weeks of age on three separate days were isolated via a Langendorff-perfused 
heart preparation using enzymatic digestion as previously described.(87) After isolation, 
the cells were suspended in Tyrode's buffers with gradually increasing Ca2+ 
concentrations (0.06, 0.6, and 1.2 mM, pH 7.4 at room temperature) and were loaded 
with 1 μM fura-2AM calcium indicator (Molecular Probes, Eugene, OR, USA) as 
previously described.(88) Myocytes were washed 3 times for 10-15 minutes with 1.2 
mM Ca2+ Tyrode's solution containing 250 μM probenecid to retain the indicator in the 
cytosol. The experiments were then performed at room temperature in 1.2 mM Ca2+ 
Tyrode's solution containing (in mM): NaCl 140, KCl 4.5, MgCl2 0.5, glucose 5, and 
HEPES 10, pH adjusted to 7.4 with NaOH.  
Cardiomyocytes were electrically paced at 60 bpm via platinum wires. Sarcomere 
shortening/relengthening and fura-2 fluorescence ratios (which reflect the intracellular 
calcium transients) were simultaneously recorded and determined from discrete striation 
positions on the myocyte using a dual-excitation fluorescence imaging/contractility 
recording system (IonWizard® SarcLen detection and PMT Acquisition fluorescence 
system, IonOptix Inc., Milton, MA, USA).  Sarcomere length and Ca2+ transients were 
analyzed using the IonOptix transient analysis software. Myocytes included in the study 
were rod-shaped with a clear striation pattern, quiescent in the absence of electrical 
stimulation and resting sarcomere length of more than 1.6 μm. A minimum of 7 
myocytes were profiled from each animal. Statistical analysis was performed with a two 
sample one-tailed student t-test. 
Electron microscopy 
Left ventricular tissue from three pairs of wildtype and Micu2-/- littermates at 18 
weeks of age were evaluated in a blinded fashion with 7 representative fields per mouse 
imaged at 1900x resolution on a Tecnai G² Spirit BioTWIN transmission electron 
microscope (FEI, Hillsboro, Oregon). The average mitochondrial size and eccentricity 
was automatically quantitated with CellProfiler (Broad Institute, Cambridge, MA). 
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Pharmacologic manipulation of blood pressure 
To increase mouse blood pressure, mice were chronically infused with 
angiotensin II (Sigma-Aldrich) dissolved in saline at 1.4 mg/kg/day or 2.8 mg/kg/day or 
norepinephrine dissolved in saline at 5.6 mg/kg/day, via an osmotic minipump for two 
weeks. (89) 
Blood pressure measurement 
Systolic blood pressure was measured in trained conscious mice using a Visitech 
BP-2000 Analysis System (Visitech Systems, Apex, NC) as previously described.(90) 
Mice were restrained on a heated device to maintain body temperature during the 
measurements. The mice were “trained” to the procedure twice every day for 3 
consecutive days, and data were recorded over the following 2 days. For each mouse, 
at least 10 readings were collected and used for statistical analysis.  
Transcriptome wide analyses 
Human tissue samples from HCM patients were obtained from study participants 
undergoing either myectomy heart surgery, cardiac transplant surgery, or valve 
replacement surgery under IRB approved protocols at Brigham and Women’s Hospital.  
RNA from human tissues and mouse LV was prepared and RNA-Seq libraries 
were constructed as previously described (91). Uniform amplification of the cDNA library 
was achieved with amplification cycling before the reaction reached saturation, as 
determined by quantitative PCR. Aorta RNA-Seq libraries were constructed with the 
Nextera library preparation method (92). To reduce biological variation in mouse 
specimens, RNA was pooled from three biological replicates for LV samples and Ang2 
treated aorta samples. For the basal aorta RNA-Seq samples, libraries from three 
biological replicates for each genotype (Micu2-/- and wildtype) were constructed and the 
libraries were sequenced individually.  
Libraries were sequenced on an Illumina HiSeq 2000 sequencer with 50 base 
pair paired-end reads. Following sequencing, alignment of reads to the mm10 genome 
was performed with Bowtie and Tophat (93). Gene expression profiles were constructed 
by tallying reads on gene loci, using a Bayesian P value to assess the significance of 
gene expression differences between pooled samples. (94) Cuffdiff 2 was used for 
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assessing significance of gene expression differences in aorta rna-seq library 
replicates.(95)  
Genes were considered differentially expressed if there was a >40% increase or 
decrease in fold change with p<10-3. The DCM mouse model and HCM mouse model 
transcriptome datasets were previously described. (74, 96)  Gene ontology  pathway 
enrichment analysis was performed with the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID).(97) 
Single Cell RNA-seq  
Mouse aortas were dissected and digested into single cells using collagenase. 
Cells were captured, RNA extracted, and amplified into cDNA libraries using the 
Fluidigm C1 system (Fluidigm, San Francisco, CA) as previously described.(98) 
Libraries were sequenced on an Illumina HiSeq 2000 sequencer with 50 base pair 
paired-end reads. Reads were aligned using Tophat. The expression of known markers 
for vascular lineages was used to classify each cell as a smooth muscle cell (Acta2, 
Tagln, Myh11), fibroblast (Vim), or endothelial cell (Pecam1, Tek, Cdh5). Cells lacking 
any of these markers were classified as ‘undetermined.’ Wilcox and fisher test p-values 
were calculated in the R statistical computing environment, version 2.15. 
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Results  
Evolutionary Diversity of the Mitochondrial Calcium Uniporter 
We examined the phylogenomic distribution of the uniporter across 162 
sequenced eukaryotic genomes, including six newly sequenced unicellular 
opisthokont/unikont genomes.  First we constructed a eukaryotic tree of life based on 16 
highly conserved proteins (Figure 1A and Figure 2).  The tree is consistent with previous 
reconstructions of the eukaryotic tree of life and as expected places the newly 
sequenced unicellular opisthokonts between fungi and metazoans.  Next we utilized a 
sequence similarity strategy followed by manual inspection to annotate organisms 
whose genomes harbor homologs of MCU and MICU1 (Figure 1A, B). 
Homologs of MCU are widely distributed across major branches of eukaryotic 
life.  They are present in all green plants and in virtually all metazoans, with the 
exceptions being the primitive metazoans T. adherens and B. maylai and the silkworm 
B. mori.  As we previously reported, MCU homologs are missing in S. cerevisiae, and 
more generally, they are not found in any of the 22 non-filamentous fungi analyzed 
here.  However, MCU homologs are found in a large number of filamentous fungi (e.g., 
N. crassa) as well as in many basidiomyces such as C. neoformans and M. perniciosa. 
As we previously reported, kinetoplastids harbor homologs of MCU (49, 50), but further 
analysis of protozoa indicate that they are absent in apicocomplexa, as well as in highly 
diverged mitosome-containing protozoa such as G. lamblia and T. vaginalis.  The fact 
that MCU homologs are present in protists, fungi, metazoans, and plants suggest that it 
must have been an early feature of eukaryotic life and perhaps lost in certain fungal and 
protozoan lineages. 
Genomes of most eukaryotes typically have both MCU and MICU1 homologs or 
lack both proteins (Figure 1A).  Perhaps the most striking exception to this rule are 
MCU-containing fungi, where MICU1 homologs have been lost altogether, suggesting 
that regulation of uniporter activity is fundamentally different in this clade.  The earliest 
branching fungus, A. macrogynus is the sole exception, which contains both MCU and 
MICU1 homologs.  Interestingly, greater diversity in MCU coiled-coil domain structure is 
also observed in these fungi.  For example, C. neoformans and M. perniciosa show 
circularly permuted arrangements of coiled-coil domains rather than a coiled-coil 
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domains bracketing the transmembrane domain as is typically observed (Figure 1b). 
While the circularly permuted coiled-coil domain arrangement is not unique to the fungi 
(e.g. A. thaliana), the increased protein divergence may be coincident with the loss of 
MICU1.  Only two organisms (T. adherens, B. mori) lacking MCU have homologs of 
MICU1, raising the hypothesis that mitochondria from these organisms either do not 
uptake calcium or have an alternate channel.  As MICU1 homologs are also found in 
protozoa, plants, metazoans, and unicellular opisthokonts, it is likely that the earliest 
eukaryote also harbored this regulator, but lost in fungal and certain protozoal lineages. 
We previously reported that human MCU and MICU1 physically interact and are 
strongly co-expressed across different mammalian organs (49). One mechanism for 
ensuring co-expression in space and time is co-localization within the genome.  
Interestingly, while MICU1 and MCU are not adjacent to each other in most of the 
analyzed genomes, all vertebrate genomes harbor these genes adjacent to each other, 
with a potential bi-directional promoter (Figure 1C), offering a mechanistic basis for their 
coordinate expression in vertebrates. 
Finally we asked if any bacteria harbor homologs of this new class of calcium 
channels.  Iterative sequence similarity and protein domain searches revealed in three 
diverse Bacteroidetes/Chlorobi  group bacteria (Prevotella oris, Chlorobium 
phaeobacteroides, and Cytophaga hutchinsonii) putative MCU homologs that we now 
term “mitochondrial uniporter homologs” (uni).  The C. hutchinsonii uni is particularly 
intriguing given its highly similar domain organization and conservation of residues 
essential for calcium transport (Figure 1B).  Clearly, functional studies are required to 
determine if bacterial uni proteins are also cationic channels.  If shown to transport 
calcium, they would represent the first prokaryotic calcium channels. 
Integrative Transcriptomic Analysis implicates Mitochondrial Calcium 
Uniporter Regulatory Subunit MICU2 in Cardiovascular Homeostasis 
Our bioinformatic screen intersected nine differentially expressed left ventricle 
transcriptome datasets. Seven datasets are derived from human heart tissue from 
patients with HCM (Table 1). Two datasets are derived from mouse models of DCM 
(PLN p.R9C)(99) and HCM (MYH6 p.R403Q)(100). Only six genes are consistently 
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differentially expressed across all nine transcriptome profiles: MICU2, DAPK3, 
PRKAB2, IGFBP6, RHEB and UCP2 (Figure 3A). 
MICU2, a calcium sensing regulatory subunit of the mitochondrial calcium 
uniporter complex localized in the mitochondrial intermembrane space (49, 53, 57), is a 
particularly intriguing candidate as cardiac calcium dysregulation is frequently observed 
in cardiomyopathy, and mitochondrial calcium overload is a key determinant in ischemic 
heart failure (101, 102). Furthermore recent studies link Mcu, the gene encoding the 
pore forming subunit of the mitochondrial calcium uniporter, to cardiac and skeletal 
muscle phenotypes. In particular, on a cellular level Mcu plays a key role in matching 
cardiac metabolism to contractile stress (70, 71) and controlling heart rate.(68) A Mcu-/- 
knockout mouse characterized by Finkel and colleagues, exhibits altered skeletal 
muscle metabolism and peak performance, however these mice did not have grossly 
altered cardiac function at baseline or in response to stress from an isoproterenol 
challenge or transverse aortic constriction (62, 66). Notably, a distinct dominant 
negative Mcu mouse model described by Anderson and colleagues had altered cardiac 
oxygen utilization, cytoplasmic Ca2+ homeostasis, and pathologic responses to 
ischemia-reperfusion injury.(69) Thus we prioritized MICU2 for further characterization.   
As altering cellular calcium prevents the development of cardiomyopathy in a 
mouse model (103), we hypothesize that increased MICU2 expression may be a cardio-
protective compensatory mechanism in the face of cardiac remodeling and thus deletion 
of MICU2 would result in cardiac dysfunction.  
Characterization of a global MICU2 knockout mouse 
To evaluate the role of MICU2 in cardiovascular homeostasis, we generated a 
global Micu2-/- mouse using a gene trap vector (Figure 3B, Figure 4A; see Methods). 
Mating Micu+/- x Micu+/- mice produced Micu+/-, and Micu2-/- offspring in expected 
Mendelian ratios.   Micu+/-, and Micu2-/- mice were of identical size to wild-type 
littermates and routinely lived >18 months. As expected, the Micu2+/- mouse had 
approximately 50% Micu2 expression in hepatic, renal and cardiac tissue and the 
Micu2-/- mouse expressed 0.05-0.15 fold normal Micu2 mRNA levels in heart, kidney 
and liver (Figure 4B). Micu2 protein was significantly reduced on immunoblot of both 
Micu2-/- mouse left ventricle and liver tissue (Figure 3C, Figure 4C). Consistent with 
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prior results of RNAi targeting Micu2 in mouse liver (53), Micu1 and Mcu protein levels 
were significantly reduced in the Micu2-/- mouse in liver tissue (Figure 4C). In the heart, 
Mcu protein expression was reduced by ~30% by immunoblot densitometry (Figure 3C). 
Also consistent with prior results, Micu2-/- mitochondria take up a high concentration 
pulse of calcium more slowly than wildtype mitochondria (56),  but uptake a small pulse 
of calcium more rapidly (Figure 5), consistent with a role for MICU2 in setting the 
threshold for the uniporter. Together these results demonstrate that the Micu2-/- mouse 
is functionally deficient in Micu2 protein activity. 
We characterized the cardiac structure and function of Micu2-/- mice with 
histology, electron microscopy and longitudinal echocardiography. Micu2-/- mice and 
wildtype littermates had histologically indistinguishable hearts without evidence of 
differences in cellularity, cell size, or fibrosis (Figure 3, D and E). We observed no gross 
ultrastructural differences in sarcomere structure in Micu2-/- cardiac tissue by electron 
microscopy (Figure 3, F and G). However, mitochondria average area in Micu2-/- mice 
was ~20% smaller than wildtype mice (p=0.003; see Methods) and the Micu2-/- mice 
mitochondria tended to be ~5% more eccentric (p=0.002; see Methods; n: >1000 
mitochondria measured from wild-type and mutant hearts) on automated quantification 
of mitochondria size and shape. 
Micu2-/- mice have left atrial enlargement at 16-18 months of age on longitudinal 
echocardiography (20% increased diameter, p=0.01, Figure 3H, see Methods). No 
significant differences were identified in ventricular chamber dimensions or fractional 
shortening. (Figure 3I, Table 2). As left atrial enlargement reflects the cumulative effect 
of increased ventricular filling pressure over time, which exists in diastolic dysfunction, 
(104, 105), we hypothesized that these echocardiographic measurements were 
consistent with diastolic cardiac dysfunction.   
To better characterize the cellular basis of Micu2-/- diastolic dysfunction, we 
performed single myocyte functional studies and global transcriptional studies of left 
ventricular myocardium (see Methods). We isolated myocytes from three pairs of WT 
and Micu2-/- littermates at 6-8 weeks of age and profiled the sarcomere contractility and 
cytosolic calcium transients.  
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Consistent with diastolic dysfunction, isolated single cardiomyocytes from Micu2-/- 
mice have altered relaxation kinetics (Figure 6, A and B, Table 3). In particular, Micu2-/- 
cardiomyocytes have similar contraction as wildtype cardiomyocytes as characterized 
by change in sarcomere length and speed of contraction, but Micu2-/- cardiomyocytes 
have a decreased rate of relaxation (p=0.02).  
As myocyte contractility and relaxation kinetics are determined, at least in part, 
by cytosolic calcium fluxes, we hypothesized that Micu2-/- mice would have altered 
cytosolic calcium transients (Figure 6, A and B, Table 4). Micu2-/- cardiomyocytes have 
similar magnitude calcium fluxes as wildtype cardiomyocytes, however the time 
constant for calcium reuptake was increased in Micu2-/- cardiomyocytes (p=0.03). 
Together the cardiomyocyte profiling suggests that individual cardiomyocytes in Micu2-/- 
mice are slower to reuptake cytosolic calcium causing a decreased rate of myocyte 
relaxation. In aggregate, this cellular phenotype results in diastolic dysfunction. 
Global transcriptional profiling with RNA-seq identified significant transcriptional 
differences in left ventricular tissue of Micu2-/- mice compared to wildtype littermates at 
18 weeks of age. 781 genes were differentially expressed. We analyzed these genes in 
an unbiased way with DAVID gene set enrichment analysis, and observed significant 
enrichment in four gene ontologies (Figure 6C): sarcomere genes (Fold enrichment: 5.9, 
p=6x10-8), bZIP transcription factors (Fold enrichment: 8.1, p=1.1x10-8), stress response 
(Fold: 7.1, p=0.01), ribosomal proteins (Fold 8.4, p=0.002). We partitioned the 
differentially expressed gene list into genes that are primarily expressed (defined as >5 
fold difference in expression between myocytes and fibroblasts) in myocytes (n=64) and 
primarily expressed in fibroblasts (n=89), with the remainder of the genes expressed in 
both fibroblasts and myocytes. Repeating the pathway analysis on these two gene sets, 
identified the sarcomere gene enrichment and oxidative phosphorylation in the myocyte 
subset and the bZIP transcription factor enrichment in the fibroblast gene subset. We 
further considered a manually curated gene set of 18 genes consistently observed as 
differentially regulated in left ventricular tissue in animals with cardiac hypertrophy 
(Myh6, Myh7, Acta2, Fhl1, Fhl2, Nppa, Nppb, Col1a1, Postn, S100a4, Tgfb1, Tgfb2, 
Tgfb3, Clu, Xirp2, Tnni3, Tnnt2, Rcan1).  Seven of the eighteen (Myh7, Acta2, Clu, 
Nppa, Nppb, Rcan1, Xirp2) were differentially expressed (OR: 15, p:4x10-6). We also 
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considered a previously described set of 1100 genes that encode for mitochondrial 
proteins (30, 106). Only 46 of the differentially expressed genes in the left ventricular 
tissue were included in this set (OR 1.1, p=NS), suggesting that the altered gene 
expression were not confined to the mitochondrial organelle. Two of the most significant 
changes in the RNA-seq dataset, were a 1.6 fold down regulation of sarcomere 
component Myh7 (p<1e-50) and a 2.9 fold down regulation of the apelin receptor (Aplnr; 
p=1e-40) in Micu2-/- left ventricles. The magnitude of these changes were independently 
confirmed with qPCR of whole heart tissue (Figure 6D). 
Angiotensin 2 induces cardiac and vascular dysfunction in Micu2-/- mouse 
Next we evaluated whether Micu2-/- hearts display exacerbated pathologic 
phenotypes in response to pharmacologic stimuli of cardiac hypertrophy, angiotensin 2 
(107). We hypothesized that Micu2-/- mice might be particularly sensitive to angiotensin 
2, because the apelin receptor (Aplnr) suppresses angiotensin II type 1 receptor 
signaling via allosteric trans-inhibition (108, 109) and Aplnr was transcriptionally down 
regulated. Homozygous Micu2-/- mice, heterozygous Micu2+/- mice and wildtype 
littermates were infused with 1.2 mg/kg/day of angiotensin 2, which resulted in an 
equivalent ~25 mmHg increase in systolic blood pressure over baseline (p<0.001, 
Figure 7A). After 2 weeks of angiotensin 2 infusion, all three sets of mice had equivalent 
increases in cardiac wall thickness suggesting that all had the same degree of 
hypertrophic remodeling (Figure 7B). While the wildtype mice had no significant change 
in fractional shortening compared to baseline, Micu2+/- mice and Micu2-/- mice had a 
significant decrease in fractional shortening, a measure of systolic cardiac function 
(p=0.04 and p=0.002 respectively, Figure 7C). Micu2-/- mice also had significantly less 
fractional shortening than wildtype mice given the same dose of Ang2.  Consistent with 
decreases in fractional shortening, Micu2-/- hearts also decreased systolic strain 
(p=0.007, Figure 7D) as measured by cardiac ultrasound speckle tracking imaging.  
While evaluating the effect of angiotensin 2 induced hypertension on Micu2-/-mice 
(1.2 mg/kg/day), three of fourteen Micu2-/- mice died unexpectedly within the first week 
from abdominal aortic aneurysm rupture as manifest by hemoperitoneum on 
postmortem exam (p=0.03, Figure 8A). This suggested Micu2 plays a role in vascular 
homeostasis.  
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We tested the hypothesis that abdominal aorta dilatation of Micu2-/- was 
angiotensin 2 dose dependent.  Micu2-/- mice were infused with either 1.2 mg/kg/day or 
2.4 mg/kg/day of angiotensin 2 and blood pressure and aortic dimensions were 
measured. The higher angiotensin 2 dose elevated blood pressure significantly more 
than the lower dose (Figure 7A). Abdominal aortic diameter was measured with 
ultrasound after 2 weeks of angiotensin 2 treatment (Figure 8B).  Absent angiotensin 2, 
Micu2-/- mice have approximately 5% larger abdominal aortic artery diameters on 
abdominal aorta ultrasound than wildtype mice (p=0.002).  Micu2-/- mice had 
significantly larger abdominal aorta diameters and the angiotensin 2 effect was dose 
dependent (Micu2-/- genotype: p=0.0003, Ang2 dose: p=0.0006). Estimated 
conservatively, since those Micu2-/- mice with ruptured their aortas could not be 
assessed by ultrasound but likely had the largest aortic diameters, Micu2-/- aortas 
increased at least 4.5 fold more than wildtype aortas in response to angiotensin 2. 
To evaluate when the abdominal aorta diameters in Micu2-/- mice increased 
compared to wildtype mice, we measured abdominal aorta diameters serially using 
ultrasound (Figure 8C, Table 5). Both Micu2-/- mice and wildtype mice abdominal aortas 
increased by ~10% on the second day. By day four, the diameter of the Micu2-/- mice 
had significantly (p=0.005) larger abdominal aortas. The Micu2-/- mice continued to 
increase in diameter, while the wildtype aorta diameter stabilized (Figure 8C). 
To determine if the increased aortic diameter was specific to angiotensin 2 or 
reflected blood pressure elevation in general, hypertension was induced in Micu2-/- with 
norepinephrine. The norepinephrine dose (5.6 mg/kg/day) equivalently elevated blood 
pressure as 1.2 mg/kg/day angiotensin 2 dosing (Figure 7A). Notably, mice treated with 
norepinephrine had no increased abdominal aortic diameter over baseline, suggesting 
that abdominal aortic dilatation phenotype is specifically angiotensin 2 mediated and not 
solely due to elevated blood pressure (Figure 8B). 
Global and Single-Cell Transcriptional profiling of Micu2-/- mouse aorta 
suggests mechanism for Angiotensin 2 induced aneurysm formation 
We used RNA-seq and pathway analysis to compare mRNA levels in Micu2-/- 
and wild-type aortas. RNAseq analyses of three pairs of aortas from 8-12 week old 
Micu2-/- mice and wildtype littermates in the basal state and after two weeks of 
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angiotensin 2 infusion (1.2 mg/kg). In the basal state, 478 genes were significantly 
down-regulated and 819 genes were significantly up-regulated in Micu2-/- mice 
compared to wildtype. Pathway analysis in DAVID identified enrichment in 23 pathways 
from the set of down-regulated genes and 18 pathways from the set of up-regulated 
genes (Figure 9A). Notably up-regulated gene sets, significant after Bonferroni 
correction, include genes enriched in oxidation reduction reactions (3.7 fold enrichment, 
p=6.2 x 10-28), mitochondrial genes (2.8 fold enrichment, p=2.4 x 10-35) and genes 
related to the peroxisome (7.0 fold enrichment, p=6.0 x 10-13). Notably down-regulated 
gene sets include myofibril (9.2 fold enrichment, p=1.6 x 10-16), extracellular matrix (5.3 
fold enrichment, p=6.59 x 10-10), cell adhesion (3.4 fold enrichment, p=3.1 x 10-12), 
blood vessel development (3.3 fold enrichment, p=0.01), growth factor binding (6.2 fold 
enrichment, p=0.002) and Wnt signaling (4.8 fold enrichment, p=0.002). These baseline 
differences in Micu2 deficient mice are consistent with a 5% increased abdominal aortic 
artery diameters (p=0.002, Figure 9B) in the absence of angiotensin 2 treatment and an 
increased susceptibility to angiotensin mediated aneurism development. Notably, while 
there is some overlap between the myofibril gene set and the sarcomere gene set 
dysregulated in the heart, the majority of these enrichment categories were not 
transcriptionally dysregulated in the heart, demonstrating tissue specificity of the Micu2-/- 
phenotype. 
To identify how angiotensin 2 alters aorta transcriptional profiles, we performed 
pathway analysis on genes differentially expressed in the angiotensin 2 treated mice 
that were not differentially expressed in the basal state. This set included 180 up-
regulated genes and 603 down-regulated genes, which fell in 7 up-regulated pathways 
and 9 down-regulated pathways. Transcription of inflammatory response genes (7 fold 
enrichment, p=8.7 x 10-5) and extracellular matrix genes (7.2 fold, 3.2 x 10-9) were 
significantly enriched in the set of up-regulated genes and transcription of cell junction 
genes were enriched in the set of down-regulated genes (2.8 fold, p=4.4 x 10-4).  
Abdominal aortic aneurysms may result from changes in the intima, media or 
adventitial layers, which are a heterogeneous collection of fibroblast, smooth muscle 
and endothelial cells. Histologic evaluation of Micu2-/- and wildtype mouse aortas did not 
favor one subset of cells (Figure 8A, inset). Because the aorta consists of primarily 
27 
 
smooth muscle cells and fibroblasts, we assessed which cell type was most perturbed 
by angiotensin 2 in wildtype and Micu2-/- aortas.   
To deconvolute cellular transcriptional heterogeneity and characterize the early 
transcriptional changes present in Micu2-/- mouse aortas, we utilized single cell RNA-
seq. Single cells from wildtype and Micu2-/- aortas after four days of angiotensin 2 
treatment were captured on a microfluidic chip, reverse-transcribed to cDNA, barcoded 
and amplified. The resulting libraries were sequenced. About 60 smooth muscle and 
fibroblast cells were isolated from angiotensin 2 treated Micu2-/- and wildtype aortas 
(Figure 9D).  Few endothelial cells were captured, likely due to their smaller cell 
diameter relative to the size of the microfluidic capture chip.  The relative distribution of 
cell types was the same in the Micu2-/- and wildtype aortas (p=NS). 
In the wildtype aorta, Micu2 was robustly expressed in 50% of the endothelial 
cells, 23% of smooth muscle cells and 18% of fibroblast cells sequenced. This was 
further suggested by robust lacZ staining of all layers of the Micu2-/- abdominal aorta. 
Thus absence of Micu2 may affect all of these cell types.  
Two patterns of gene expression differences were observed: (1) differences in 
the absolute level of gene expression, quantitated with a Wilcox test on median 
difference (Figure 9E) and (2) differences in the number of cells that expressed a given 
gene at an appreciable level, quantitated with a Fisher test (Figure 9F). A bonferoni-
adjustment for significance was set at p<1x10-5 to reflect the ~5,000 genes expressed. 
At this strict threshold, six genes were differentially expressed in smooth muscle cells 
and five genes were differentially expressed in fibroblasts. Analysis of endothelial cells 
was underpowered as only 10 cells were captured, consequently, no genes exceeded 
the significance threshold.  
Among the six genes differentially expressed in smooth muscle cells, notable 
differences include upregulation of genes associated with increased inflammatory and 
reactive oxygen species (ROS) states in Micu2-/- cells (Figure 9, E and F). Significantly 
more Micu2-/- smooth muscle cells expressed extracellular glutathione peroxidase Gpx3 
(96% of Micu2-/-, 29% of wild type cells), inflammatory cytokinesTnfaip6 and Ccl11 as 
well as transcription factor Irf1, which is associated with inflammatory state. Also, while 
the majority of both Micu2-/- and wildtype smooth muscle cells expressed 
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metallothionein Mt1 which contributes to cardiovascular protection in high ROS states, 
the median expression was 9 fold higher in Micu2-/- smooth muscle cells (p=7.5 x 10-8). 
The five genes differentially expressed in Micu2-/- fibroblasts are involved in 
proliferative response, inflammation and ROS (Figure 9, E and F). Of the Micu2-/- 
fibroblasts, 80% expressed the pro-proliferative transcription factor Myc compared to 
10% of WT cells (p=1.5 x10-6). Concordantly, Nme2, a negative regulator of Rho 
signaling, which activates Myc, had two-fold decreased expression in the Micu2-/- 
fibroblasts (p=4.9 x 10-6). 88% of Micu2-/- fibroblasts expressed Efemp1, which induces 
EGFR autophosphorylation and downstream activation of cell adhesion and migration, 
compared to 10% of the WT fibroblasts (9.6 x10-8). Concordantly, Egr1, an activator of 
differentiation and mitogenesis genes, had three-fold increased expression in Micu2-/- 
fibroblasts (p=2.5 x10-6).  Micu2-/- fibroblasts also had differential gene expression of 
inflammatory and ROS genes including significantly decreased expression of Fmo3 and 
Sod3 which reduce ROS free radicals and differential expression of inflammatory 
mediators Il6 and C1qb.  
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Discussion, Conclusions, and Future Work 
Evolutionary Diversity of the Mitochondrial Calcium Uniporter 
Calcium uptake by mitochondria was discovered at the same time that 
mechanisms of chemiosmotic coupling were being deciphered, yet the molecular basis 
has only recently been resolved.  The presence of MCU and MICU1 homologs in all 
major branches of eukaryotic life, suggest that it may play a far more fundamental role 
in eukaryotic cell physiology than previously anticipated.  Our characterization of the 
uniporter’s phylogenomic distribution and protein structures may guide physiological 
studies that may help establish the role of this channel in primitive eukaryotes, and may 
aid in elucidating its regulatory mechanisms. The putative identification of bacterial 
homologues of MCU, if experimentally confirmed, will be among the first calcium 
channels identified in bacteria.  
Role of Micu2 in Cardiac Homeostasis 
Our data establish a critical role for the mitochondrial calcium uniporter and 
specifically Micu2 in maintaining both cardiac and vascular homeostasis in physiologic 
and pathophysiologic states. The absence of Micu2 in normal physiologic states is 
associated with echocardiographic measurements consistent with cardiac diastolic 
dysfunction (isolated left atrial enlargement) and a decreased rate of relaxation on a 
single myocyte profiling. Myocytes lacking Micu2, have an increased time constant for 
cytosolic calcium reuptake suggesting a cellular mechanism. The physiologic stress of 
these altered calcium dynamics is evidenced by the transcriptional signature of Micu2-/- 
cardiac tissue which is characterized by sarcomere dysregulation, stress response 
pathways and altered expression of sarcomere genes and bZIP family of transcription 
factors, which are associated with cardiomyopathy pathogenesis (9, 10, 110-112). 
In pathophysiologic cardiovascular states, the importance of Micu2 is even more 
evident. In the setting of hypertension, Micu2 knockout mice exhibit systolic cardiac 
dysfunction as evidenced by decreased fractional shortening and altered systolic strain 
measurements on speckle tracking imaging. Thus the hypertension stimuli appear to 
accelerate and accentuate the observed natural phenotype of left atrial enlargement 
with diastolic dysfunction. Although heart failure in the setting of normal cardiac 
dimensions termed “heart failure with preserved ejection fraction” is increasingly 
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observed clinically (113), animal models have yet to replicate this disease trajectory. 
The Micu2-/- mice, which have diastolic dysfunction but normal cardiac dimensions, may 
represent a first step in this direction.   
Mechanistically, the molecular pathways underlying diastolic dysfunction are 
incompletely understood. On a cellular level, cardiomyocyte relaxation requires tightly 
bound actin-myosin filaments to detach, which is mediated by decreased levels of 
cytosolic calcium, hence any process that reduces calcium resequestration into cellular 
calcium stores (eg sarcoplasmic reticulum, mitochondria) or extrusion out of the cell can 
result in delayed relaxation (114). Proteins implicated in altered calcium handling in 
failing hearts include: the sarcoplasmic reticular Ca2+-ATPase (SERCA2a) and its 
modulator phospholamban (PLB); the SR–Ca2+ release channel and its modulator FK-
506 binding protein 12.6 (FKBP12.6), and the sodium-calcium exchanger (NCX) (115-
118). It is possible that MICU2 acts similarly to the PLB or FKBP12.6 proteins, sensing 
calcium levels outside mitochondria and dynamically gating the calcium uptake of the 
mitochondrial calcium uniporter. 
Our data is consistent with other recent findings highlighting the importance of 
the mitochondrial calcium uniporter in maintaining cardiac homeostasis in physiologic 
and pathological states (62, 66, 68-71).  However, diastolic cardiac dysfunction and 
systolic dysfunction in response to Angiotensin 2 has not previously been described. 
Whether the cardiac phenotype we observe in the Micu2-/- mice reflects differences in 
the molecular role of Micu2 and Mcu or the specific nature of Angiotensin 2 perturbation 
or remains to be determined. 
Overall, significant work remains to understand how the absence of Micu2 gives 
rise to these physiologically significant changes to cardiac function. Mitochondrial 
calcium in general and the calcium uniporter is thought to be a relatively small calcium 
store in the context of the numerous ways that the cardiac myocyte buffers calcium 
(119). It is tempting to speculate that the loss of Micu2 plays a role in altering the 
dynamics of calcium reuptake in the myocyte. In mitochondria from hepatocytes, which 
do not have significant other calcium buffering mechanisms, Micu2-/- mitochondria 
uptake high concentrations of calcium significantly more slowly than wildtype 
mitochondria (53, 56). However, the cardiac myocyte is flooded with high concentrations 
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of calcium with every contraction. Thus the slower mitochondrial calcium uptake may 
play a role in altering the cardiac calcium dynamics as evidenced by the decreased 
cytosolic calcium reuptake we observed. 
Role of Micu2 in Vascular Homeostasis 
In the setting of angiotensin 2 induced hypertension, Micu2-/- mice are prone to 
lethal abdominal aortic aneurysms. The transcriptional state of the Micu2-/- aorta is 
consistent with known transcriptional mechanisms of aneurysm formation involving a 
pro-inflammatory state with increased extracellular matrix remodeling and cellular 
proliferation in human patients and animal models (120-124). Matrix metalloproteinase 3 
(Mmp3), which degrades collagen, fibronectin, laminin, and elastin is one of the most 
significantly upregulated genes. Polymorphisms in the Mmp3 gene have been 
associated with aneurism formation in human patients(125, 126) and a mouse lacking 
Mmp3 has reduced aneurism formation (127). Concordant with the collagen 
degradation induced by Mmp3 upregulation, several collagens are unregulated after 
angiotensin 2 exposure including Col3a1 and Col1a2, both of which are known causes 
of Ehlers-Danlos syndrome (128-130). Similarly other genes linked to familial aneurism 
syndromes, Fbn1 and Tgfb2 which are slightly downregulated in the basal state are 
upregulated after angiotensin 2 exposure (131-133). 
Inflammatory response genes Serpina3n and Thbs1 are upregulated in response 
to Angiotensin 2. Serpina3n is an inhibitor of proapoptotic serine protease Granzyme B 
which contributes to aortic aneurysm through ECM cleavage. Serpina3n is a 
compensatory protective response to angiotensin 2 exposure.(134) Conversely, 
Thrombospondin-1 (Thbs1) contributes to a vascular pro-inflammatory state and 
aneurysm formation (135). 
Insulin-like growth factor binding protein 2 (Igfbp2) was significantly down-
regulated in the basal state and up-regulated after angiotensin 2 stimulation. Igfbp2 
signals through epidermal growth factor receptor (EGFR) to potentiate STAT3 
activation. Both Stat3 and Egfr are associated with abdominal aneurism formation in 
human patients and animal models (136, 137). 
Calgranulins S100a8 and S100a4 are similarly downregulated in the basal state 
and upregulated after angiotensin infusion and may directly link altered calcium flux 
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caused by Micu2 to aneurysm. Calgranulins are a family of small acidic calcium 
signaling proteins that promote inflammation and vascular disease by activating 
RAGE(138) and are linked to vascular dysfunction and atherosclerosis.(139, 140) 
S100a4 is strongly upregulated in the aortic wall of human thoracic aortic (141) and 
intracranial aneurysms (142). S100a4 silencing decreases vascular smooth proliferation 
and matrix metalloproteinase expression (141). 
Notably, the Micu2-/-aneurysm phenotype is angiotensin 2 dose dependent but is 
not simply mediated by blood pressure as raising blood pressure with norepinephrine 
does not result in aortic dilatation, implicating Angiotensin 2 specific signaling. 
Angiotensin 2 has been shown to activate noncanonical TGFβ signaling (ERK1/2) via 
protein kinase C (143, 144). Altered TGF-Beta signaling is a common pathway of 
familial aortic aneurysm syndromes including FBN1 mutations associated with Marfan 
syndrome, TGFBR1/2 mutations associated with Loeys–Dietz and SMAD3/4 mutations 
associated with familial thoracic aortic aneurysms (131-133, 145). Recent work by Dietz 
and colleagues, demonstrated that mouse models of Marfan disease treated with 
calcium channel blockers, had accelerated thoracic aortic aneurysm expansion and 
rupture through a protein kinase C mediated pathway, suggesting that crosstalk 
between calcium signaling and TGFβ may cause aneurysms (146). Additionally, clinical 
evidence supports the link between calcium and aneurysm formation. For example, a 
large retrospective study of human patients with AAA found calcium channel blockers to 
be an independent risk factor for AAA (147). These results also motivate future 
investigation into how altered mitochondrial calcium homeostasis contributes to 
abdominal aortic aneurysms, as it is distinct from well described aneurysm syndromes  
Angiotensin 2 is also known to mediate mitochondrial dysfunction via a protein 
kinase C dependent pathway by activating the endothelial cell NADPH oxidase and 
modulating NO· and O2- generation, which causes vascular dysfunction (148). Current 
rodent models of abdominal aortic aneurysms rely heavily on mice with atherogenic 
mutations and aneurysms in these mice are thought to be mediated by reactive oxygen 
species (149, 150). Loss of the Micu2 paralog, Micu1, results in oxidative stress and 
vascular dysfunction (151). Thus given the transcriptional changes we observed in both 
whole tissue and single cell RNA-seq which reflect transcriptional changes associated 
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oxidative stress, it is likely that the Micu2 mouse aneurysm is also caused by oxidative 
stress. Regardless, the Micu2-/- mouse described here represents a distinctly different 
mouse model from atherogenic mutation models and may provide new insights into 
disease pathogenesis and therapeutics. Future work in understanding the interplay 
between mitochondrial calcium homeostasis and AAA may identify new mechanisms 
amenable to therapeutic intervention. 
Human patients with two MICU2 loss of function mutations have not yet been 
reported. However, patients with MICU1 homozygous loss of function mutations have a 
skeletal muscle myopathy and learning difficulties with extrapyramidal symptoms.(72) 
Although cardiovascular disease was not described as a phenotypic disease feature, 
MICU1 and MICU2 form a protein-protein complex (56), so it is possible that these 
patients have a subclinical cardiovascular phenotype or may develop cardiovascular 
disease in the future. Patients identified with MICU2 loss of function mutations in the 
future should be closely followed for evidence of cardiovascular disease and may 
benefit from treatment that decreases angiotensin 2 signaling. 
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Summary 
In this dissertation, I characterize the evolutionary origin of an ancient and 
ubiquitous biochemical process – the uptake of calcium by mitochondria and 
demonstrate that this function prevents cardiac and vascular disease.  Calcium uptake 
into the mitochondria occurs via a recently identified macromolecular complex: the 
mitochondrial calcium uniporter. I first characterize the phylogenomic distribution of the 
uniporter’s membrane spanning pore protein (MCU) and regulatory subunits (MICU1 
and MICU2) across 162 eukaryotic genomes. Reconstructing a phylogenomic tree of 
life, reveals homologs of both MCU and MICU1 tend to co-occur in all major branches of 
eukaryotic life but both have been lost along certain protozoan and fungal lineages. 
Together this suggests that the uniporter was an early feature of mitochondria and that 
both pore and regulatory subunits are important in its function. The wide distribution of 
the uniporter, suggests that it plays an important role in eukaryotes. 
Transcriptome wide analysis of human and mouse cardiomyopathy datasets 
identifies MICU2 as consistently upregulated in disease. To test the hypothesis that 
increased MICU2 expression is cardio-protective, we generated a global Micu2-/- 
mouse.  At baseline, Micu2-/- mice have diastolic cardiac dysfunction. When stressed 
with angiotensin 2, Micu2-/- mice exhibit systolic cardiac dysfunction and developed 
lethal abdominal aortic aneurysms. Single-cell RNA-sequencing of the aorta identified 
differential reactive oxygen species, inflammation and proliferation in Micu2-/- aortas 
suggesting a mechanism for aneurism formation. Together, these data point to a 
significant and previously unappreciated role for Micu2 in maintaining both cardiac and 
vascular homeostasis.   
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Figure 1. (A) Eukaryotic tree of life annotated with presence of MCU (black) and MICU1 
(red) homologs, detailed version available in Figure 2. (B) Protein domain architecture 
of MCU homologs, including mitochondrial targeting sequence (white rectangle), coiled-
coil domain (coil), transmembrane domain (shaded rectangle), and the DIME motif. (C) 
Genomic organization of MICU1 and MCU across vertebrate genomes.  
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Figure 2. Eukaryotic tree of life annotated with MCU (black) and MICU1 (red) 
homologs.    
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Figure 3. Integrative analysis of transcriptome datasets and characterization of 
the Micu2-/- mouse hearts. (A) Integration of RNA-seq profiles from human and mouse 
cardiomyopathy. Intersecting seven human HCM patient cardiac muscle transcriptomes 
with mouse models of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy 
(DCM) identified 6 consistently differentially expressed genes including mitochondrial 
calcium uniporter component Micu2. (B) Schema of Micu2 gene trap vector used to 
generate the Micu2-/- mouse. (C) Protein levels of the mitochondrial calcium uniporter 
regulatory component Micu2 were significantly reduced in Micu2-/- mouse hearts. 
Uniporter core calcium channel Mcu had ~30% decreased protein expression. (D and 
E). Hearts of Micu2-/- mice were histologically indistinguishable from wildtype littermates. 
(F and G) Representative electron microscopy sections of Micu2-/- and wildtype mouse 
hearts. Scale bar: 10 um. H-I. Longitudinal evaluation by echocardiography identified 
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increased left atrial (LA) size consistent with diastolic dysfunction but no significant 
differences in interventricular septum (IVS), posterior wall (PW) thickness. 
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Figure 4. Gene trap disruption of Micu2 locus. (A) Schematic showing the mouse 
Micu2 genomic locus, highlighting where the gene trapping vector is inserted. The gene 
trap vector (VICTR 37) has a β-Geo selection marker, along with a splice acceptor (SA) 
and transcription termination sequence (pA) and is flanked by retroviral long terminal 
repeat sequences. The genomic DNA sequence surrounding the gene trap vector 
insertion site is shown. The insertion site is indicated with a red asterisk. (B) Micu2+/- 
mice had a 50% reduction in Micu2 expression across liver, kidney and heart by qPCR. 
Micu2-/- mice had further reduced levels of Micu2 expression. (C) Protein levels of the 
mitochondrial calcium uniporter complex components MICU2, MICU1 and MCU were all 
significantly reduced in Micu2-/- mouse liver tissue.   
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Figure 5. Micu2-/- mouse liver mitochondria take up Ca2+ slower at high [Ca2+] and 
faster at low [Ca2+]. (A and B). Isolated mouse liver mitochondria were given a pulse of 
(A) ~25 μM or (B) ~2 μM CaCl2. Extramitochondrial [Ca2+] was measured using the 
membrane-impermeable calcium indicator Oregon Green BAPTA6F.  (C) Relative rates 
of calcium uptake from experiments such as those in A and B at different injected [Ca2+] 
in isolated mouse liver mitochondria (n=3).   
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Figure 6. Functional, structural and transcriptional analysis of Micu2-/- 
cardiomyocytes. (A) Representative tracings of single myocyte sarcomere length 
(plotted as % of resting length) and calcium flux (plotted as normalized Fura-2 intensity) 
in Micu2-/- mice and wildtype littermates. (B) Micu2-/- cardiomyocytes had slower 
repolarization kinetics as evidenced by both decreased sarcomere relaxation velocity 
and increased time constant (Tau) for calcium reuptake compared to wildtype 
cardiomyocytes. (C) Transcriptome wide analysis of Micu2-/- and wildtype left ventricular 
tissue revealed enrichment in three gene sets: sarcomere components, stress response 
genes and bZip transcription factors. Plotted P-values are bonferoni-corrected. (D) 
Micu2, Myh7 and Aplnr were three of the most differentially expressed genes in the left-
ventricle RNA-seq datasets. Fold change differences in these genes were 
independently confirmed with quantitative-PCR in whole heart tissue from n=5 mice. 
Mean and standard deviation of Micu2-/- qPCR expression normalized to mean wildtype 
qPCR expression are plotted.  
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Figure 7. Micu2-/- mice have increased susceptibility to Angiotensin 2 mediated 
hypertensive dysfunction. (A) Micu2-/- and wildtype mice have equivalent systolic 
blood pressures at baseline and equivalently elevated pressures after angiotensin 2 
infusion (1.2 mg/kg/day, 2.4 mg/kg/day) and norepinephrine infusion (5.6 mg/kg/day). (B 
and C) After 2 weeks of angiotensin 2 infusion, Micu2-/- mice have equivalent increases 
in left ventricular wall thickness (LV WT) in response to the hypertrophic stimuli, but 
have significantly worse systolic function as quantified by decrease in fractional 
shortening (FS). (D) Speckle tracking imaging analysis identifies decreased systolic 
tissue strain in Micu2-/- mice after two weeks of angiotensin 2 infusion consistent with 
systolic dysfunction. (*) p<0.05 (**) p<0.01, (***)p<0.001  
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Figure 8. Micu2-/- mice are susceptible to angiotensin 2 induced aortic aneurisms. 
(A) Micu2-/- mice were observed to have an increased propensity to die from abdominal 
aortic aneurism rupture when stressed by angiotensin 2 (1.2 mg/kg, p=0.03). Inset: 
representative abdominal aorta histological sections after 2 weeks of angiotensin 2 
infusion demonstrate grossly similar histologic patterns. (B) Abdominal Aortic diameter 
(AbAo) measured at baseline and 2 weeks after angiotensin 2 infusion identified slightly 
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enlarged aortic diameters of Micu2-/- mice at baseline that was greatly exaggerated with 
increasing angiotensin 2 dose (2.4 mg/kg). However, aorta diameter does not change in 
the presence of norepinephrine. (C) Serial measurements of abdominal aorta diameter 
in Micu2-/- and wildtype mice identified a differential aortic enlargement by day 4 of 
angiotensin 2 infusion (2.4 mg/kg).  (*) p<0.05, (**) p<0.01 
  
64 
 
 
Figure 9. Transcriptional dissection of Micu2-/- aortic aneurysm. (A) RNA-seq 
pathway enrichment analysis of Micu2-/- gene expression compared to wildtype mice in 
the basal state without angiotensin infusion identifies numerous gene sets in genes that 
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are up-regulated (shaded bars) and down-regulated (unshaded bars). P-values are 
bonferoni corrected. (B) RNA-seq pathway enrichment analysis of mouse aorta tissue 
after 2 weeks of angiotensin 2 infusion (1.2 mg/kg) identified 3 notable expressed gene 
sets: an upregrulation of inflammatory response and ECM genes and a down-regulation 
of cell-junction genes. (C) Fold change of selected genes with known roles in aneyurism 
formation in the basal and Ang2 (1.2 mg/kg) state with significant differential expression 
by RNA-seq. (D) To elucidate early transcriptional changes leading to aneurysm 
formation, two mice were treated with high dose Angiotensin 2 (2.4 mg/kg) for 4 days. 
Aortas were dissected and captured on a microfluidic chip. Gene expression at the 
single cell level was analyzed. 63 cells from wildtype aortas and 60 cells from Micu2-/- 
aortas were available for analysis. The majority of single cells captured on the 
microfluidic chip were smooth muscle and fibroblast cells with a distinct minority of 
endothelial cells. This distribution was likely due to the size of the microfluidic chip. (E) 
In the wildtype mouse aorta single cells, Micu2 was expressed in 50% of endothelial 
cells, 23% of smooth muscle cells and 14% of fibroblasts. Inset: LacZ staining of 
Micu2+/- mouse aorta reveals gross Micu2 expression throughout the aorta suggesting 
that Micu2 expression is not limited to a single cell type. Scale bar is 500 um. (F and G) 
For smooth muscle and fibroblast cells, differences in level of gene expression were 
assessed with a Wilcox test and differences in the percent of cells expressing a 
transcript (defined as >5FPKM) was assessed with a Fisher test. Conservatively 
correcting for multiple hypothesis testing, 3 genes were differentially expressed in terms 
of level of expression (F) and 8 genes were differentially expressed in terms of percent 
of cells expression a transcript (G). The 11 genes were involved in cellular response to 
reactive oxygen species or cellular proliferation. (H) Transcriptional changes associated 
with Ang2 mediated abdominal aortic aneyurism formation in Micu2-/- mice. Single cell 
RNA-seq data identifies an inflammatory and ROS response at 4 days. Whole tissue 
RNA seq at 2 weeks identifies transcriptional upregulation of insulin growth factor (IGF) 
signaling, matrix metaloproteases (MMP), S100a4/8 and Aplnr as well as extracellular 
matrix (ECM) disregulation.  
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Table 1. Patient characteristics of myectomy samples used in bioinformatic 
screen. 
Sample Gender Age at diagnosis 
Age at 
myectomy 
LV wall 
thickness 
(mm) 
Genotype 
1 Female 49 69 27 MYH7 p.A1051V 
2 Female 45 52 18 MYH7 p.Y833H 
3 Female 67 69 13 MYH7 p.G741R 
4 Female 46 52 15 TNNT2 p.D81A 
5 Female 26 45 18 Negative 
6 Male 43 45 23 Negative 
7 Male 31 31 32 Negative 
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Table 2. Echocardiography of WT and MICU2-/- mice at 16-18 weeks. 
 WT (N=5) MICU2-/- 
(N=6) 
P 
Age 16.97 (1.1) 16.92 (0.54) 0.94 
Weight 43.66 (8.64) 36.08 (6.61) 0.15 
Interventricular Septum (Mm) 0.93 (0.05) 0.87 (0.07) 0.11 
Left Ventricular Diastolic Diameter 
(Mm) 
3.32 (0.4) 3.48 (0.41) 0.53 
Left Ventricular Posterior Wall (Mm) 0.82 (0.09) 0.85 (0.04) 0.43 
Fractional Shortening (%) 48.6 (9.2) 48.4 (5.7) 0.97 
Left Atrial Diameter (Mm) 1.5 (0.1) 1.8 (0.2) 0.01 
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Table 3. Single myocyte sarcomere transient measurements. 
 WT  
(n=34 
cells) 
MICU2-/-  
(n=22 cells) 
p 
∆ sarcomere length 
(%)  
 
4.14 
(1.95) 
3.81 (2.11) 0.28 
Depolarization 
velocity 
-1.09 
(0.71) 
-0.86 (0.54) 0.1 
Repolarization 
velocity 
0.54 
(0.69) 
0.26 (0.17) 0.02 
Repolarization time 
constant (Tau) 
0.27 
(0.17) 
0.33 (0.14) 0.06 
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Table 4. Single myocyte calcium transient measurements. 
 WT  
(n=31 cells) 
MICU2-/-  
(n=22 cells) 
p 
Total calcium flux 0.08 (0.04) 0.08 (0.03) 0.4 
Depolarization 
velocity 
22.79 
(23.38) 
29.24 (34.19) 0.21 
Repolarization 
velocity 
-3.85 (6.17) -2.74 (3.45) 0.22 
Repolarization time 
constant (Tau) 
0.17 (0.04) 0.22 (0.08) 0.03 
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Table 5. Aorta diameter time course after Ang 2 (2.4 mg/kg). 
 WT MICU2-/- P 
DAY N Mean (mm) Std. dev. N Mean (mm) Std. dev  
0 5 0.971 0.033 5 1.022 0.032 0.042 
2 5 1.087 0.077 5 1.163 0.114 0.26 
4 5 1.069 0.070 5 1.227 0.030 0.0048 
7 10 0.985 0.068 8 1.233 0.085 3.81E-06 
14 9 1.029 0.130 8 1.344 0.307 0.024 
 
 
